AZTR receives NYSE delisting warning over equity requirement
SAN DIEGO - Tandem Diabetes Care, Inc. (NASDAQ:TNDM), currently trading at $12 per share with annual revenues exceeding $1 billion, announced Monday that its t:slim X2 insulin pump with Control-IQ+ automated insulin delivery technology has received clearance for use with Eli Lilly’s Lyumjev ultra-rapid acting insulin in the United States. According to InvestingPro data, the company maintains healthy liquidity with a current ratio of 2.44, indicating strong operational capability.
The clearance applies to people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes, expanding insulin options for pump users. The approval was based on a 13-week multicenter study involving 179 individuals that demonstrated high satisfaction and quality of life benefits, according to the company’s press release. Despite this positive development, InvestingPro analysis shows the company faces near-term profitability challenges, with 15 analysts revising their earnings expectations downward.
"This latest milestone reinforces our commitment to facilitating choice and access for people who rely on insulin therapy," said Jordan Pinsker, Chief Medical Officer at Tandem Diabetes Care.
Lyumjev was authorized for general use in insulin pumps in the U.S. in 2021, but pump manufacturers must conduct extensive testing to verify compatibility with specific insulin pumps and automated insulin delivery systems.
The t:slim X2 pump is now cleared in the U.S. for use with three insulin options: Humalog, Novolog, and Lyumjev U-100 insulins. Tandem and Lilly are continuing to work toward securing Lyumjev compatibility for the Tandem Mobi pump.
Lyumjev is available through the Lilly Insulin Value Program, which allows individuals with commercial insurance or no insurance to fill monthly prescriptions for $35, subject to terms and conditions.
Tandem Diabetes Care manufactures automated insulin delivery systems designed to reduce the burden of diabetes management. The company’s pump portfolio includes the Tandem Mobi system and the t:slim X2 insulin pump. While the company has achieved impressive revenue growth of 25.84% over the last twelve months, InvestingPro subscribers have access to comprehensive analysis including Fair Value estimates, 8+ additional ProTips, and detailed financial health scores that can help investors make more informed decisions about this medical device manufacturer.
In other recent news, Tandem Diabetes Care reported its second-quarter 2025 earnings, revealing a loss per share of $0.78, which missed analysts’ expectations of $0.40. Despite a revenue surprise, the earnings disappointment led to a decline in the company’s stock price. Following the earnings report, TD Cowen lowered its price target for Tandem Diabetes Care to $20.00 from $27.00, citing reduced U.S. sales guidance for 2025. Barclays also adjusted its price target to $51.00 from $53.00, noting that while international sales exceeded expectations, U.S. sales underperformed. Oppenheimer maintained its Outperform rating but reduced the price target to $22.00 due to an internal analyst reallocation. CFRA also lowered its price target to $22.00 from $33.00, highlighting concerns over GLP-1 risks and widening its net loss forecasts for 2025 and 2026. These updates reflect ongoing challenges and adjustments in analyst expectations for Tandem Diabetes Care.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.